{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T06:27:10Z","timestamp":1781245630403,"version":"3.54.1"},"reference-count":134,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T00:00:00Z","timestamp":1632528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Cancer immunotherapy significantly contributed to an improvement in the prognosis of cancer patients. Immunotherapy, including human epidermal growth factor receptor 2 (HER2)-targeted therapies, immune checkpoint inhibitors (ICI), and chimeric antigen receptor-modified T (CAR-T), share the characteristic to exploit the capabilities of the immune system to kill cancerous cells. Trastuzumab is a monoclonal antibody against HER2 that prevents HER2-mediated signaling; it is administered mainly in HER2-positive cancers, such as breast, colorectal, biliary tract, and non-small-cell lung cancers. Immune checkpoint inhibitors (ICI) inhibit the binding of CTLA-4 or PD-1 to PDL-1, allowing T cells to kill cancerous cells. ICI can be used in melanomas, non-small-cell lung cancer, urothelial, and head and neck cancer. There are two main types of T-cell transfer therapy: tumor-infiltrating lymphocytes (or TIL) therapy and chimeric antigen receptor-modified T (CAR-T) cell therapy, mainly applied for B-cell lymphoma and leukemia and mantle-cell lymphoma. HER2-targeted therapies, mainly trastuzumab, are associated with left ventricular dysfunction, usually reversible and rarely life-threatening. PD\/PDL-1 inhibitors can cause myocarditis, rare but potentially fulminant and associated with a high fatality rate. CAR-T therapy is associated with several cardiac toxic effects, mainly in the context of a systemic adverse effect, the cytokines release syndrome.<\/jats:p>","DOI":"10.3390\/cancers13194797","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T01:59:47Z","timestamp":1632707987000},"page":"4797","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Cardiac Toxicity Associated with Cancer Immunotherapy and Biological Drugs"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3150-399X","authenticated-orcid":false,"given":"Andrea","family":"Montisci","sequence":"first","affiliation":[{"name":"Division of Cardiothoracic Intensive Care, ASST Spedali Civili, 25123 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Vietri","sequence":"additional","affiliation":[{"name":"Department of Precision Medicine, University of Campania \u201cLuigi Vanvitelli\u201d, 81100 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Palmieri","sequence":"additional","affiliation":[{"name":"Department of Cardiac Surgery and Transplantation, Ospedali dei Colli Monaldi-Cotugno-CTO, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Sala","sequence":"additional","affiliation":[{"name":"Department of Anesthesia and Intensive Care, University of Brescia, 25121 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Donatelli","sequence":"additional","affiliation":[{"name":"Cardiac Surgery, University of Milan, 20122 Milan, Italy"},{"name":"Department of Cardiac Surgery, Istituto Clinico Sant\u2019Ambrogio, 20149 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Napoli","sequence":"additional","affiliation":[{"name":"Clinical Department of Internal Medicine and Specialistics, University Department of Advanced Clinical and Surgical Sciences, University of Campania \u201cLuigi Vanvitelli\u201d, 81100 Naples, Italy"},{"name":"IRCCS SDN, 80143 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"232","DOI":"10.2174\/2211738506666180918122337","article-title":"Drug Delivery for Cancer Immunotherapy and Vaccines","volume":"6","author":"Batty","year":"2018","journal-title":"Pharm. Nanotechnol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s40265-020-01281-4","article-title":"Trastuzumab Deruxtecan: First Approval","volume":"80","author":"Keam","year":"2020","journal-title":"Drugs"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-11-1595","article-title":"Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma","volume":"17","author":"Lipson","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental Mechanisms of Immune Checkpoint Blockade Therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s40265-018-1012-5","article-title":"Cemiplimab: First Global Approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"90215","DOI":"10.18632\/oncotarget.21652","article-title":"Structural Basis of the Therapeutic Anti-PD-L1 Antibody Atezolizumab","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5532","DOI":"10.1038\/s41598-017-06002-8","article-title":"Molecular Mechanism of PD-1\/PD-L1 Blockade via Anti-PD-L1 Antibodies Atezolizumab and Durvalumab","volume":"7","author":"Lee","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Ahmad, A. (2020). CAR-T Cell Therapy. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21124303"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11886-021-01440-3","article-title":"Immunotherapy-Associated Cardiotoxicity of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T Cell Therapy: Diagnostic and Management Challenges and Strategies","volume":"23","author":"Rothberg","year":"2021","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"180037","DOI":"10.1098\/rsob.180037","article-title":"Cancer Immunotherapy: Broadening the Scope of Targetable Tumours","volume":"8","author":"Verdegaal","year":"2018","journal-title":"Open Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients with Relapsed Low-Grade Non-Hodgkin\u2019s Lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-Lineage Cells and Regression of Lymphoma in a Patient Treated with Autologous T Cells Genetically Engineered to Recognize CD19","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Naing, A., and Hajjar, J. (2020). Immunotherapy. Advances in Experimental Medicine and Biology, Springer International Publishing. [3rd ed.].","DOI":"10.1007\/978-3-030-41008-7"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/cvr\/cvz026","article-title":"Cardiovascular Toxicities Associated with Immune Checkpoint Inhibitors","volume":"115","author":"Hu","year":"2019","journal-title":"Cardiovasc. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3389\/fcvm.2019.00003","article-title":"Cardiac Complications in Immune Checkpoint Inhibition Therapy","volume":"6","author":"Tajiri","year":"2019","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","article-title":"Immune Checkpoint Inhibitors and Cardiovascular Toxicity","volume":"19","author":"Lyon","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11912-020-00925-8","article-title":"New Insights into Mechanisms of Immune Checkpoint Inhibitor-Induced Cardiovascular Toxicity","volume":"22","author":"Khunger","year":"2020","journal-title":"Curr. Oncol. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal Neoantigens Elicit T Cell Immunoreactivity and Sensitivity to Immune Checkpoint Blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic Correlates of Response to CTLA-4 Blockade in Metastatic Melanoma","volume":"350","author":"Miao","year":"2015","journal-title":"Science"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e439","DOI":"10.1200\/JCO.2012.47.7521","article-title":"Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma","volume":"31","author":"Philips","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S2468-1253(16)30014-0","article-title":"Somatic POLE Proofreading Domain Mutation, Immune Response, and Prognosis in Colorectal Cancer: A Retrospective, Pooled Biomarker Study","volume":"1","author":"Domingo","year":"2016","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e1264565","DOI":"10.1080\/2162402X.2016.1264565","article-title":"Immunological Profiling of Molecularly Classified High-Risk Endometrial Cancers Identifies POLE-Mutant and Microsatellite Unstable Carcinomas as Candidates for Checkpoint Inhibition","volume":"6","author":"Eggink","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13045-020-00862-w","article-title":"Next-Generation Immuno-Oncology Agents: Current Momentum Shifts in Cancer Immunotherapy","volume":"13","author":"Pan","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMra043186","article-title":"Trastuzumab--Mechanism of Action and Use in Clinical Practice","volume":"357","author":"Hudis","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1365-2249.2011.04477.x","article-title":"Differential Inhibition of Trastuzumab- and Cetuximab-Induced Cytotoxicity of Cancer Cells by Immunoglobulin G1 Expressing Different GM Allotypes","volume":"166","author":"Namboodiri","year":"2011","journal-title":"Clin. Exp. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1002\/jcp.29216","article-title":"Overcoming Trastuzumab Resistance in HER2-Positive Breast Cancer Using Combination Therapy","volume":"235","author":"Derakhshani","year":"2020","journal-title":"J. Cell Physiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","article-title":"HER2-Targeted Therapies\u2014A Role beyond Breast Cancer","volume":"17","author":"Oh","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1158\/1535-7163.MCT-15-0741","article-title":"Trastuzumab, but Not Pertuzumab, Dysregulates HER2 Signaling to Mediate Inhibition of Autophagy and Increase in Reactive Oxygen Species Production in Human Cardiomyocytes","volume":"15","author":"Mohan","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","article-title":"Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience","volume":"20","author":"Seidman","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1200\/JCO.2011.35.6725","article-title":"Overall Survival Benefit with Lapatinib in Combination with Trastuzumab for Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Final Results from the EGF104900 Study","volume":"30","author":"Blackwell","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(11)61847-3","article-title":"Lapatinib with Trastuzumab for HER2-Positive Early Breast Cancer (NeoALTTO): A Randomised, Open-Label, Multicentre, Phase 3 Trial","volume":"379","author":"Baselga","year":"2012","journal-title":"Lancet"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1200\/JCO.2015.62.1797","article-title":"Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and\/or Trastuzumab Treatment Optimization Trial","volume":"34","author":"Holmes","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer","volume":"372","author":"Swain","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1703643","article-title":"Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer","volume":"377","author":"Procter","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S1470-2045(14)70178-0","article-title":"Trastuzumab Emtansine versus Treatment of Physician\u2019s Choice for Pretreated HER2-Positive Advanced Breast Cancer (TH3RESA): A Randomised, Open-Label, Phase 3 Trial","volume":"15","author":"Krop","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1200\/JCO.2014.58.7782","article-title":"Feasibility and Cardiac Safety of Trastuzumab Emtansine after Anthracycline-Based Chemotherapy as (Neo)Adjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early-Stage Breast Cancer","volume":"33","author":"Krop","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1200\/JCO.2016.67.4887","article-title":"Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study","volume":"35","author":"Perez","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jamaoncol.2016.0237","article-title":"Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial","volume":"2","author":"Awada","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/S1470-2045(17)30717-9","article-title":"Neratinib after Trastuzumab-Based Adjuvant Therapy in HER2-Positive Breast Cancer (ExteNET): 5-Year Analysis of a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"18","author":"Martin","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s12032-016-0797-x","article-title":"Anthracycline- and Trastuzumab-Induced Cardiotoxicity: A Retrospective Study","volume":"33","author":"Hamirani","year":"2016","journal-title":"Med. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.echo.2015.02.001","article-title":"Time Trends of Left Ventricular Ejection Fraction and Myocardial Deformation Indices in a Cohort of Women with Breast Cancer Treated with Anthracyclines, Taxanes, and Trastuzumab","volume":"28","author":"Tan","year":"2015","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Moja, L., Tagliabue, L., Balduzzi, S., Parmelli, E., Pistotti, V., Guarneri, V., and D\u2019Amico, R. (2012). Trastuzumab Containing Regimens for Early Breast Cancer. Cochrane Database Syst. Rev., CD006243.","DOI":"10.1002\/14651858.CD006243.pub2"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1177\/2042098614529603","article-title":"Cardiovascular Toxicity Associated with Adjuvant Trastuzumab Therapy: Prevalence, Patient Characteristics, and Risk Factors","volume":"5","author":"Onitilo","year":"2014","journal-title":"Ther. Adv. Drug Saf."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"112","DOI":"10.15420\/cfr.2018.32.2","article-title":"Heart Failure and Cancer: Mechanisms of Old and New Cardiotoxic Drugs in Cancer Patients","volume":"5","author":"Cuomo","year":"2019","journal-title":"Card. Fail. Rev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/S0735-1097(99)00396-4","article-title":"Reliability of Echocardiographic Assessment of Left Ventricular Structure and Function: The PRESERVE Study. Prospective Randomized Study Evaluating Regression of Ventricular Enlargement","volume":"34","author":"Palmieri","year":"1999","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0735-1097(95)00153-Q","article-title":"Geometric Changes Allow Normal Ejection Fraction despite Depressed Myocardial Shortening in Hypertensive Left Ventricular Hypertrophy","volume":"26","author":"Aurigemma","year":"1995","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"7820","DOI":"10.1200\/JCO.2005.13.300","article-title":"Reversibility of Trastuzumab-Related Cardiotoxicity: New Insights Based on Clinical Course and Response to Medical Treatment","volume":"23","author":"Ewer","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1200\/JCO.2004.06.557","article-title":"Safety of Treatment of Metastatic Breast Cancer with Trastuzumab beyond Disease Progression","volume":"22","author":"Tripathy","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1200\/JCO.2007.11.0106","article-title":"Trastuzumab-Related Cardiotoxicity: Calling into Question the Concept of Reversibility","volume":"25","author":"Telli","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2165\/00002018-200831060-00002","article-title":"Cardiotoxicity Profile of Trastuzumab","volume":"31","author":"Ewer","year":"2008","journal-title":"Drug Saf."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1200\/JCO.2009.27.3615","article-title":"Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation","volume":"28","author":"Cardinale","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1161\/CIRCRESAHA.109.205906","article-title":"The Vulnerability of the Heart as a Pluricellular Paracrine Organ: Lessons from Unexpected Triggers of Heart Failure in Targeted ErbB2 Anticancer Therapy","volume":"106","author":"Doggen","year":"2010","journal-title":"Circ. Res."},{"key":"ref_57","first-page":"70","article-title":"Trastuzumab-Induced Cardiac Dysfunction: A \u201cDual-Hit\u201d","volume":"16","author":"Zeglinski","year":"2011","journal-title":"Exp. Clin. Cardiol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"289","DOI":"10.5966\/sctm.2011-0016","article-title":"Functional Impairment of Human Resident Cardiac Stem Cells by the Cardiotoxic Antineoplastic Agent Trastuzumab","volume":"1","author":"Barth","year":"2012","journal-title":"Stem Cells Transl. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1136\/heartjnl-2012-303151","article-title":"Trastuzumab-Induced Cardiotoxicity in Early Breast Cancer Patients: A Retrospective Study of Possible Risk and Protective Factors","volume":"99","author":"Farolfi","year":"2013","journal-title":"Heart"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10549-019-05303-y","article-title":"HER2+ Breast Cancer Treatment and Cardiotoxicity: Monitoring and Management","volume":"177","author":"Jerusalem","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Minichillo, S., Gallelli, I., Barbieri, E., Cubelli, M., Rubino, D., Quercia, S., Dall\u2019Olio, M., Rapezzi, C., and Zamagni, C. (2017). Trastuzumab Resumption after Extremely Severe Cardiotoxicity in Metastatic Breast Cancer Patient: A Case Report. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3712-8"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/j.transproceed.2009.06.029","article-title":"Recovery of Ventricular Function with a Left Ventricular Axial Pump in a Patient with End-Stage Toxic Cardiomyopathy Not a Candidate for Heart Transplantation: First Experience in Spain","volume":"41","author":"Castells","year":"2009","journal-title":"Transplant. Proc."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.mayocp.2014.08.011","article-title":"New-Onset Heart Failure in Association with Severe Hypertension during Trastuzumab Therapy","volume":"89","author":"Herrmann","year":"2014","journal-title":"Mayo Clin. Proc."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-Driven Biomarkers to Guide Immune Checkpoint Blockade in Cancer Therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2016.02.010","article-title":"Characterisation and Management of Dermatologic Adverse Events to Agents Targeting the PD-1 Receptor","volume":"60","author":"Belum","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of Antitumor Immunity by CTLA-4 Blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/j.athoracsur.2014.05.060","article-title":"A Meta-Analysis of Minimally Invasive versus Conventional Sternotomy for Aortic Valve Replacement","volume":"98","author":"Phan","year":"2014","journal-title":"Ann. Thorac. Surg."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/CJI.0b013e318156e47e","article-title":"Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated with Enteritis and Hypophysitis","volume":"30","author":"Yang","year":"2007","journal-title":"J. Immunother."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1053\/j.seminoncol.2010.09.010","article-title":"Clinical Development of the Anti-CTLA-4 Antibody Tremelimumab","volume":"37","author":"Ribas","year":"2010","journal-title":"Semin. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved Survival with Ipilimumab in Patients with Metastatic Melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.7150\/jca.30723","article-title":"Aging, Cancer and Immunity","volume":"10","author":"Hong","year":"2019","journal-title":"J. Cancer"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jamaoncol.2020.0237","article-title":"Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial","volume":"6","author":"Rizvi","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","article-title":"Durvalumab, with or without Tremelimumab, plus Platinum-Etoposide versus Platinum-Etoposide Alone in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (CASPIAN): Updated Results from a Randomised, Controlled, Open-Label, Phase 3 Trial","volume":"22","author":"Goldman","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40425-016-0152-y","article-title":"Cardiotoxicity Associated with CTLA4 and PD1 Blocking Immunotherapy","volume":"4","author":"Heinzerling","year":"2016","journal-title":"J. Immunother. Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1084\/jem.20090847","article-title":"PD-L1 Regulates the Development, Maintenance, and Function of Induced Regulatory T Cells","volume":"206","author":"Francisco","year":"2009","journal-title":"J. Exp. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 Is a Second Ligand for PD-1 and Inhibits T Cell Activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and Its Ligands in Tolerance and Immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu. Rev. Immunol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.4049\/jimmunol.165.3.1352","article-title":"CTLA-4 (CD152) Can Inhibit T Cell Activation by Two Different Mechanisms Depending on Its Level of Cell Surface Expression","volume":"165","author":"Carreno","year":"2000","journal-title":"J. Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1126\/science.aav7062","article-title":"Restriction of PD-1 Function by Cis-PD-L1\/CD80 Interactions Is Required for Optimal T Cell Responses","volume":"364","author":"Sugiura","year":"2019","journal-title":"Science"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14302\/issn.2471-2175.jdrt-17-1760","article-title":"Blockade of Programmed Cell Death Protein-1 Pathway for the Treatment of Melanoma","volume":"1","author":"Bhandaru","year":"2017","journal-title":"JDRT"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s13046-019-1259-z","article-title":"Combination of CTLA-4 and PD-1 Blockers for Treatment of Cancer","volume":"38","author":"Rotte","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in Previously Untreated Melanoma without BRAF Mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for Relapsed\/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial","volume":"36","author":"Armand","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in Patients with Advanced Hepatocellular Carcinoma (CheckMate 040): An Open-Label, Non-Comparative, Phase 1\/2 Dose Escalation and Expansion Trial","volume":"389","author":"Sangro","year":"2017","journal-title":"Lancet"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1001\/jama.2016.4059","article-title":"Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma","volume":"315","author":"Ribas","year":"2016","journal-title":"JAMA"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/cas.13480","article-title":"Pembrolizumab in Asia-Pacific Patients with Advanced Head and Neck Squamous Cell Carcinoma: Analyses from KEYNOTE-012","volume":"109","author":"Tahara","year":"2018","journal-title":"Cancer Sci."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s40425-016-0176-3","article-title":"Responses of Metastatic Basal Cell and Cutaneous Squamous Cell Carcinomas to Anti-PD1 Monoclonal Antibody REGN2810","volume":"4","author":"Falchook","year":"2016","journal-title":"J. Immunother. Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1080\/21645515.2019.1571892","article-title":"PD-1 and PD-L1 in Cancer Immunotherapy: Clinical Implications and Future Considerations","volume":"15","author":"Jiang","year":"2019","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_91","first-page":"140","article-title":"Atezolizumab (Tecentriq\u00ae): Activity, indication and modality of use in advanced or metastatic urinary bladder carcinoma","volume":"105","author":"Bonnet","year":"2018","journal-title":"Bull. Cancer"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e180077","DOI":"10.1001\/jamaoncol.2018.0077","article-title":"Efficacy and Safety of First-Line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial","volume":"4","author":"Russell","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S1470-2045(17)30240-1","article-title":"Avelumab for Patients with Previously Treated Metastatic or Recurrent Non-Small-Cell Lung Cancer (JAVELIN Solid Tumor): Dose-Expansion Cohort of a Multicentre, Open-Label, Phase 1b Trial","volume":"18","author":"Gulley","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/jamaoncol.2018.4628","article-title":"Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low\/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial","volume":"5","author":"Siu","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_97","unstructured":"(2021, September 14). Dose Dependence of Treatment-Related Adverse Events for Immune Checkpoint Inhibitor Therapies: A Model-Based Meta-Analysis\u2014PubMed, Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/32934874\/."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e27987","DOI":"10.4161\/onci.27987","article-title":"Adverse Cardiac Events to Monoclonal Antibodies Used for Cancer Therapy: The Risk of Kounis Syndrome","volume":"3","author":"Kounis","year":"2014","journal-title":"Oncoimmunology"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant Myocarditis with Combination Immune Checkpoint Blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/S1470-2045(18)30673-9","article-title":"Avelumab versus Docetaxel in Patients with Platinum-Treated Advanced Non-Small-Cell Lung Cancer (JAVELIN Lung 200): An Open-Label, Randomised, Phase 3 Study","volume":"19","author":"Barlesi","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as Second-Line or Third-Line Treatment in Relapsed Malignant Mesothelioma (DETERMINE): A Multicentre, International, Randomised, Double-Blind, Placebo-Controlled Phase 2b Trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1158\/1078-0432.CCR-14-2607","article-title":"Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors","volume":"21","author":"Patnaik","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11912-021-01070-6","article-title":"Cardiotoxicity of Immune Checkpoint Inhibitors","volume":"23","author":"Patel","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/nm955","article-title":"Autoantibodies against Cardiac Troponin I Are Responsible for Dilated Cardiomyopathy in PD-1-Deficient Mice","volume":"9","author":"Okazaki","year":"2003","journal-title":"Nat. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in Patients Treated With Immune Checkpoint Inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Palaskas, N., Lopez-Mattei, J., Durand, J.B., Iliescu, C., and Deswal, A. (2020). Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment. JAHA, 9.","DOI":"10.1161\/JAHA.119.013757"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.117.030571","article-title":"Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity","volume":"136","author":"Escudier","year":"2017","journal-title":"Circulation"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased Reporting of Fatal Immune Checkpoint Inhibitor-Associated Myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1634\/theoncologist.2018-0130","article-title":"Immune Checkpoint Inhibitor-Associated Myocarditis","volume":"23","author":"Ganatra","year":"2018","journal-title":"Oncologist"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ejca.2020.09.032","article-title":"How to Manage Patients with Corticosteroids in Oncology in the Era of Immunotherapy?","volume":"141","author":"Aldea","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_116","first-page":"832","article-title":"CAR-T Therapy Is Approved for Mantle Cell Lymphoma","volume":"324","author":"Voelker","year":"2020","journal-title":"JAMA"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Boni, C., Barili, V., Acerbi, G., Rossi, M., Vecchi, A., Laccabue, D., Penna, A., Missale, G., Ferrari, C., and Fisicaro, P. (2019). HBV Immune-Therapy: From Molecular Mechanisms to Clinical Applications. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20112754"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Maude, S.L., Laetsch, T.W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M.R., Stefanski, H.E., and Myers, G.D. (2018). Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N. Engl. J. Med.","DOI":"10.1056\/NEJMoa1709866"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-Term Safety and Activity of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1): A Single-Arm, Multicentre, Phase 1-2 Trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.bbmt.2018.05.014","article-title":"Cardiac Profile of Chimeric Antigen Receptor T Cell Therapy in Children: A Single-Institution Experience","volume":"24","author":"Burstein","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1097\/CCM.0000000000002053","article-title":"Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia","volume":"45","author":"Fitzgerald","year":"2017","journal-title":"Crit. Care Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric Antigen Receptor T Cells Persist and Induce Sustained Remissions in Relapsed Refractory Chronic Lymphocytic Leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","article-title":"Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T)","volume":"74","author":"Alvi","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and Biomarkers of Severe Cytokine Release Syndrome after CD19 Chimeric Antigen Receptor-Modified T-Cell Therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.120.048100","article-title":"Chimeric Antigen Receptor T-Cell Therapy-Associated Cardiomyopathy in Patients With Refractory or Relapsed Non-Hodgkin Lymphoma","volume":"142","author":"Ganatra","year":"2020","journal-title":"Circulation"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jaccao.2020.04.012","article-title":"Cardiovascular Effects of CAR T Cell Therapy: A Retrospective Study","volume":"2","author":"Lefebvre","year":"2020","journal-title":"JACC CardioOncol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jaccao.2020.02.011","article-title":"CAR T Cell Therapy\u2013Related Cardiovascular Outcomes and Management: Systemic Disease or Direct Cardiotoxicity?","volume":"2","author":"Ghosh","year":"2020","journal-title":"JACC CardioOncol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-018-0918-x","article-title":"The Biological Basis and Clinical Symptoms of CAR-T Therapy-Associated Toxicites","volume":"9","author":"Titov","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine Storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-018-0571-y","article-title":"Grading of Cytokine Release Syndrome Associated with the CAR T Cell Therapy Tisagenlecleucel","volume":"11","author":"Porter","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1182\/blood-2018-99-112023","article-title":"Late Effects of CD19-Targeted CAR-T Cell Therapy","volume":"132","author":"Cordeiro","year":"2018","journal-title":"Blood"},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Montisci, A., Palmieri, V., Liu, J.E., Vietri, M.T., Cirri, S., Donatelli, F., and Napoli, C. (2021). Mechanisms of Severe Cardiac Toxicity Induced by Cancer Therapies in Patients Requiring Intensive Care Unit. Front. Cardiovasc. Med., in press.","DOI":"10.3389\/fcvm.2021.713694"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/19\/4797\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:04:47Z","timestamp":1760166287000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/19\/4797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,25]]},"references-count":134,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["cancers13194797"],"URL":"https:\/\/doi.org\/10.3390\/cancers13194797","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,25]]}}}